The Foundation for NIH (FNIH) https://fnih.org, and the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) https://niddk.nih.gov within NIH, have announced a new partnership to investigate links across serious common diseases that researchers believe may share the same biological causes.
Using a patient-centric approach, the Accelerating Medicines Partnership for Common Metabolic Diseases (AMP CMD) will focus on clarifying links among six serious metabolic diseases, to include obesity, type 2 diabetes, prediabetes, cardiovascular diseases, kidney diseases and liver diseases. NIDDK and four pharmaceutical companies are investing $57 million over five years to support AMP CMD.
The four pharmaceutical companies Amgen, Eli Lilly and Company, Novo Nordisk, and Pfizer Inc. will provide $17 million to AMP CMD to complement the $40 million in research funding that is being provided by NIDDK. The FNIH will provide program and project management over the next five years.
The new partnership will build on scientific advances and analytical tools developed as part of a previous AMP research program in type 2 diabetes, including a Knowledge Portal. The Knowledge Portal is a rich database of genetic information from more than 1.5 million individuals with diabetes and related conditions worldwide.
AMP CMD will add substantial amounts of new information from participants in studies from the other metabolic diseases and develop new tools to analyze the links between them. The resulting data will be made broadly and be rapidly available to the scientific research community.